A Randomized Study Comparing Venetoclax and Azacitidine to Induction Chemotherapy for Newly Diagnosed Fit Adults with Acute Myeloid Leukemia
Brief description of study
This research is being done to see how an investigational combination of study drugs works in comparison to chemotherapy in people with acute myeloid leukemia.
This study involves the following study drug combinations. You will only receive
one of these combinations:
• Venetoclax and azacitidine (investigational combination)
• Cytarabine and idarubicin or daunorubicin (per standard of care)
• Liposomal daunorubicin and cytarabine (per standard of care)
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Acute Myeloid Leukemia
-
Age: Between 18 Years - 99 Years
-
Gender: All
Male or Female, Age 18 or older, Acute Myeloid Leukemia
Updated on
09 Mar 2024.
Study ID: 850133
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
